Company / PP&E (Net)
UroGen Pharma Ltd. PP&E (Net) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$637.0K
FY2025
5-year range
$637.0K / $2.0M
FY2021-FY2025
Trend
-2.7%
vs FY2024
Sector context
#163 of 193
Health Care
What the data says
UroGen Pharma Ltd.'s pp&e (net) of $637,000 is lower than 84% of companies in the Health Care sector (FY2025). PP&E (Net) has declined for 5 consecutive years, from $2M in FY2020 to $637,000 in FY2025.
Based on SEC 10-K filings.
$637,000 in FY2025 with a 5-year CAGR of -20.8%.
Declined from $689,000 to $637,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -21.1%
- 5-Year CAGR
- -20.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 193This company $637.0K Sector average $777.6M
▼
-99.9% below sector average
Key checks
Key Insights
- UroGen Pharma Ltd.'s pp&e (net) has declined for 5 consecutive years.
- 5-year CAGR of -20.8%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 2.7% year-over-year.
- Ranks #163 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $637.0K | -2.7% |
| FY2024 | $655.0K | -4.9% |
| FY2023 | $689.0K | -46.9% |
| FY2022 | $1.3M | -34.1% |
| FY2021 | $2.0M | -3.9% |
| FY2020 | $2.0M | +109.4% |
| FY2019 | $977.0K | +3.1% |
| FY2018 | $948.0K | +17.8% |
| FY2017 | $805.0K | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026